Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: A phase 3, randomized, double-blind study

Journal of Clinical Psychiatry

Volumn 76, Issue 9, 2015, Pages 1232-1240

  Thase, Michael E ^a   Youakim, James M ^b   Skuban, Aleksandar ^b   Hobart, Mary ^b   Zhang, Peter ^b   McQuade, Robert D ^b   Nyilas, Margaretta ^b   Carson, William H ^b   Sanchez, Raymond ^b   Eriksson, Hans ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^c H LUNDBECK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BREXPIPRAZOLE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; PAROXETINE; PLACEBO; SERTRALINE; VENLAFAXINE; QUINOLONE DERIVATIVE; THIOPHENE DERIVATIVE;

ABNORMAL INVOLUNTARY MOVEMENT SCALE; ABNORMAL LABORATORY RESULT; ADJUVANT THERAPY; ADULT; AGED; AKATHISIA; ANXIETY; ARTICLE; BARNES AKATHISIA SCALE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DSM-IV-TR; EPILEPSY; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEMALE; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; RHINOPHARYNGITIS; SEDATION; SHEEHAN DISABILITY SCALE; SIDE EFFECT; SOMNOLENCE; SUICIDAL IDEATION; SUICIDE; TREMOR; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; ADOLESCENT; CLINICAL TRIAL; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DOSE RESPONSE; DRUG COMBINATION; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; QUINOLONES; THIOPHENES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84942502726     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.14m09689     Document Type: Article

References (43)

1. Ferrari AJ, Somerville AJ, Baxter AJ, et al. Global variation in the prevalence and incidence of major depressive disorder: A systematic review of the epidemiological literature. Psychol Med. 2013;43(3):471-481.
2. Ferrari AJ, Charlson FJ, Norman RE, et al. Burden of depressive disorders by country, sex, age, and year: findings from the Global Burden of Disease study 2010. PLoS Med. 2013;10(11):e1001547.
3. Kessler RC. The costs of depression. Psychiatr Clin North Am. 2012;35(1):1-14.
4. Luppa M, Heinrich S, Angermeyer MC, et al. Cost-of-illness studies of depression: A systematic review. J Affect Disord. 2007;98(1-2):29-43.
5. Olchanski N, McInnis Myers M, Halseth M, et al. The economic burden of treatment-resistant depression. Clin Ther. 2013;35(4):512-522.
6. Connolly KR, Thase ME. If at first you don't succeed: A review of the evidence for antidepressant augmentation, combination and switching strategies. Drugs. 2011;71(1):43-64.
7. Moller HJ. Outcomes in major depressive disorder: The evolving concept of remission and its implications for treatment. World J Biol Psychiatry. 2008;9(2):102-114.
8. Fleurence R, Williamson R, Jing Y, et al. A systematic review of augmentation strategies for patients with major depressive disorder. Psychopharmacol Bull. 2009;42(3):57-90.
9. Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: A meta-analysis of placebo-controlled randomized trials. Am J Psychiatry. 2009;166(9):980-991.
10. Wright BM, Eiland EH 3rd, Lorenz R. Augmentation with atypical antipsychotics for depression: A review of evidence-based support from the medical literature. Pharmacotherapy. 2013;33(3):344-359.
11. Spielmans GI, Berman MI, Linardatos E, et al. Adjunctive atypical antipsychotic treatment for major depressive disorder: A meta-analysis of depression, quality of life, and safety outcomes. PLoS Med. 2013;10(3):e1001403.
12. Maeda K, Sugino H, Akazawa H, et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014;350(3):589-604.
13. Amada N, Maeda K, Akazawa H, et al. Brexpiprazole, a novel serotonin-dopamine activity modulator: in vivo evaluation of its antipsychotic-like profile. Society of Biological Psychiatry 69th Annual Meeting; May 8-10, 2014; New York, NY. Abstract P410.
14. Hirose T, Maeda K, Stensbol TB, et al. Synergistic effects of brexpiprazole with SSRI/SNRI/diazepam on forced swim test and marble burying behaviour in mice. Biol Psychiatry. 2014;75(suppl 1):132S.
15. Thase ME, Youakim JM, Skuban A, et al. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: A phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants. J Clin Psychiatry 2015;76(9):1224-1231.
16. American Psychiatric Association. Diagnostic and Statistical Manual for Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.
17. Chandler GM, Iosifescu DV, Pollack MH, et al. RESEARCH: validation of the Massachusetts General Hospital Antidepressant Treatment History Questionnaire (ATRQ). CNS Neurosci Ther. 2010;16(5):322-325.
18. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1): 56-62.
19. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967;6(4):278-296.
20. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education, and Welfare Publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health; 1976:218-222.
21. Thase ME, Fava M, Hobart M, et al. Efficacy of adjunctive OPC-34712 across multiple outcome measures in major depressive disorder: A phase II, randomized, placebo-controlled study. Neuropsychopharmacology. 2011;36:S302-S304.
22. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382-389.
23. Williams JBW, Kobak KA. Development and reliability of a structured interview guide for the Montgomery Asberg Depression Rating Scale (SIGMA). Br J Psychiatry. 2008;192(1):52-58.
24. Sheehan DV. The Anxiety Disease. New York, NY: Charles Scribner & Sons; 1983.
25. Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol. 1996;11(suppl 3):89-95.
26. Rush AJ, Gullion CM, Basco MR, et al. The Inventory of Depressive Symptomatology (IDS): psychometric properties. Psychol Med. 1996;26(3):477-486.
27. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50-55.
28. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand suppl. 1970;45(S212):11-19.
29. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154(5):672-676.
30. Chappell P, Feltner DE, Makumi C, et al. Initial validity and reliability data on the Columbia- Suicide Severity Rating Scale. Am J Psychiatry. 2012;169(6):662-663, author reply 663.
31. Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168(12): 1266-1277.
32. Labbate LA, Lare SB. Sexual dysfunction in male psychiatric outpatients: validity of the Massachusetts General Hospital Sexual Functioning Questionnaire. Psychother Psychosom. 2001;70(4):221-225.
33. Thase ME, Gelenberg AJ, Freeman MP, et al. Practice Guideline for the Treatment of Patients With Major Depressive Disorder, 3rd ed. Arlington, VA: American Psychiatric Association; 2010.
34. Duru G, Fantino B. The clinical relevance of changes in the Montgomery-Asberg Depression Rating Scale using the minimum clinically important difference approach. Curr Med Res Opin. 2008;24(5):1329-1335.
35. Montgomery SA, Moller HJ. Is the significant superiority of escitalopram compared with other antidepressants clinically relevant? Int Clin Psychopharmacol. 2009;24(3):111-118.
36. Bauer M, Pretorius HW, Constant EL, et al. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry. 2009;70(4):540-549.
37. El-Khalili N, Joyce M, Atkinson S, et al. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: A multicentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol. 2010;13(7):917-932.
38. Berman RM, Marcus RN, Swanink R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: A multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68(6):843-853.
39. Berman RM, Fava M, Thase ME, et al. Aripiprazole augmentation in major depressive disorder: A double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr. 2009;14(4):197-206.
40. Marcus RN, McQuade RD, Carson WH, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: A second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2008;28(2):156-165.
41. Dunlop BW, Thase ME, Wun CC, et al. A metaanalysis of factors impacting detection of antidepressant efficacy in clinical trials: The importance of academic sites. Neuropsychopharmacology. 2012;37(13):2830-2836.
42. Walsh BT, Seidman SN, Sysko R, et al. Placebo response in studies of major depression: variable, substantial, and growing. JAMA. 2002;287(14):1840-1847.
43. Thase ME, Trivedi MH, Nelson JC, et al. Examining the efficacy of adjunctive aripiprazole in major depressive disorder: A pooled analysis of 2 studies. Prim Care Companion J Clin Psychiatry. 2008;10(6):440-447.